1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support startups and small to medium-sized enterprises (SMEs) with innovative projects that have the potential for significant technological advancement and market impact. The program offers a combination of funding mechanisms, including grants and equity investments, aimed at helping companies navigate the crucial phases of development and scale.

Funding Mechanisms

Under the EIC Accelerator, there are two primary funding components:

Purpose in the Ecosystem

The EIC Accelerator plays a vital role in the European DeepTech and startup ecosystem by providing essential financial resources and support to high-potential innovations. It aims to bridge the gap between research and commercialization, thereby fostering the growth of groundbreaking technologies. By offering financial assistance, the program enables companies to attract additional funding from private sectors, thereby enhancing their chances of success in competitive markets.

Scaling and Funding Support

The EIC Accelerator not only provides funding but also connects companies with a network of investors, mentors, and industry experts. This support is crucial for startups looking to scale operations effectively. By facilitating access to private sector funding, the EIC Accelerator enhances the financial viability of innovative projects, ensuring that companies can achieve their growth objectives and contribute meaningfully to the European economy.

Case Study: SYNERGIA MEDICAL and the NAO.VNS Project

Company Overview

SYNERGIA MEDICAL is a Belgian company focused on developing innovative medical technologies. The company has gained recognition for its pioneering approaches to treating complex neurological conditions, particularly drug-resistant epilepsy.

Project Details: NAO.VNS

The project NAO.VNS stands for "A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy." The initiative aims to develop an advanced neural stimulation therapy tailored to patients who have not responded satisfactorily to conventional drug therapies.

Technology Background

The NAO.VNS project is grounded in cutting-edge neuroscience and medical technology. The technology involves the use of a neuromodulation device that delivers personalized electrical stimulation to specific neural pathways associated with epilepsy. This approach leverages the principles of neuroplasticity, allowing the brain to adapt and potentially reduce the frequency and severity of seizures.

The device is designed to be minimally invasive, offering patients a new treatment avenue that could significantly improve their quality of life. By focusing on the personalization of therapy, SYNERGIA MEDICAL aims to address the unique neurological profiles of individuals suffering from drug-resistant epilepsy, tailoring the stimulation parameters to optimize therapeutic outcomes.

The project was submitted under the EIC Accelerator's Step 2 proposal on June 15, 2022, and subsequently succeeded in the Step 3 interview, securing the necessary funding to bring this innovative treatment to market.

Conclusion

The EIC Accelerator program serves as a catalyst for innovation within the European landscape, empowering startups like SYNERGIA MEDICAL to develop transformative technologies. By providing both grant funding and equity investment, the program plays a critical role in enabling companies to scale their operations and attract further investment, ensuring that groundbreaking solutions like NAO.VNS can ultimately reach the patients who need them most.

2 The Funding Rounds

Synergia Medical: Financing and Funding Details Since EIC Accelerator Award (Belgium, June 2022)

Financing Raised and Total Funding

Since its founding, Synergia Medical has raised over €30 million, with significant funding events occurring in the period following their successful EIC Accelerator application on June 15, 2022. The company focuses on developing NAO.VNS, a non-metal optoelectronic neurostimulator for drug-resistant epilepsy.

As of January 2023, total capital raised since inception exceeded €30 million.

Funding Rounds: Timing and Amounts

• Series B Round:
• Announced September 12, 2022
• Amount: €9 million
• Purpose: To prepare for First-In-Human (FIH) clinical trials planned for early 2023 and regulatory milestones like FDA IDE submission.
• EIC Accelerator Grant:
• Announced October 19, 2022
• Amount: €2.5 million grant from the European Innovation Council (EIC), with potential additional equity investment of up to €7.5 million in future Series C fundraising rounds.
• Series B Extension:
• Announced January 18, 2023
• Additional amount: €3.8 million
• Purpose: To further prepare for FIH clinical trials now planned for early/mid-2024.
• Total Series B round after extension reached €12.8 million.

Investors Participating

Synergia Medical's post-EIC cut-off funding rounds included a mix of historical shareholders and new investors:

• Historical Private Shareholders
• Newton Biocapital (lead investor in previous rounds)
• Public Investors:
• SFPI-FPIM (Belgian Federal Holding & Investment Company)
• SRIW Life Sciences
• Investsud
• Walloon regional government support
• New/Additional Investors:
• TheClubDeal (institutional investor specializing in life sciences/technology)
• Invest BW (investment/financing company of Walloon Brabant)
• Berrebi Family Office/Bercom International

– Various private investors associated with TheClubDeal

Investor Quotes

"We are delighted to add Synergia Medical to our portfolio...having an exciting breakthrough project managed by a highly capable team as well being protected by solid patents." — Jean-Marc Legrand, CEO of TheClubDeal

“I believe that Synergia Medical’s epilepsy treatment has huge potential...” — Jacques Berrebi

Company Valuations

Available public sources indicate that after the Series B extension (€12.8M total), Synergia Medical’s valuation was reported at approximately €45 million as of January 2023. This equates to roughly a ~20x EV/LTM EBITDA multiple according to Dealroom data.

Exit Events (IPO / Buyout / Acquisition)

As of May 1st, 2025:

• There have been no publicly announced exit events such as IPOs or acquisitions involving Synergia Medical.
• The company remains private and focused on advancing pre-clinical studies towards human trials.

Summary Table

Date	Funding Round	Amount Raised	Notable Investors	Purpose
Feb.2018	Series A	€8.1M	Newton Biocapital et al.	Final device testing before CE mark submission
Sep.12,2022	Series B	€9M	Historical + Newton Biocapital + SFPI/SRIW/Investsud + Walloon region + TheClubDeal	Prep FIH trials; US FDA IDE
Oct.19,2022	EIC Grant	€2.5M grant	European Innovation Council	Non-dilutive research/development
Jan.18,2023	Series B Extension	Additional €3.8M (Total S.B.:€12.8M)	Invest BW + Berrebi family office/Bercom International + others Prepare FIH clinical trials in early/mid–24

Other Information

Synergia Medical continues to be led by CEO & Co-founder Attila Borbath; staff increased from ~25 to ~27 between late–22 and early–23 as they advanced R&D efforts toward clinical validation milestones.

There is no evidence or announcement regarding an IPO or acquisition event up through May 1st of this year.

---

Sources

• SYNERGIA MEDICAL SUCCESSFULLY RAISES SERIES B FUNDING OF €9 MILLION
• Synergia Medical Increases Series B Funding to €12.8 Million with an Additional €3.8 Million
• SYNERGIA MEDICAL INCREASES SERIES B FUNDING TO €12.8 MILLION WITH AN ADDITIONAL €3.8 MILLION
• News and Events – Synergia Medical
• Synergia raises €8 .1million in Series A – Newton Biocapital
• Syngergia company info/funding/dealroom valuation

3 The Press Releases

Synergia Medical's EIC Accelerator Achievement and Innovations Belgium-based Synergia Medical secured €2.5 million in grant funding through the European Innovation Council (EIC) Accelerator program in June 2022, with potential for an additional €7.5 million equity investment during its Series C round. The company’s winning proposal centered on NAO.VNS, a novel optoelectronic vagus nerve stimulator designed to treat drug-resistant epilepsy. This MRI-safe neurostimulator replaces traditional metal components with advanced optical materials, biosensors, and microelectronics, aiming to reduce side effects and improve patient outcomes.

Technology and Clinical Progress
NAO.VNS represents a shift toward personalized neurostimulation therapy, leveraging photonics for precise nerve targeting. Synergia has achieved ISO 13485 certification and previously commercialized an external neurostimulator for motorized prostheses. The EIC funding will support upcoming human trials to validate the device’s efficacy in epilepsy treatment.

Leadership and Recognition
Under CEO Attila Borbath, Synergia has expanded its team to 13 professionals specializing in neurostimulation technology. The company presented its innovations at the LSI Emerging Medtech Summit in 2021–2022, highlighting its role as a pioneer in photonics-based medical devices.

No recent press releases from synergia-medical.com were identified via available data. However, earlier announcements emphasized NAO.VNS’s potential as a next-generation implantable device following preclinical success.

---

Sources

• SYNERGIA MEDICAL RECOGNISED BY EIC ACCELERATOR
• European Innovation Council - Investor Database Entry
• LSI Innovator Success Stories

4 The Technology Advancements

Synergia Medical: Advancements and Developments

Overview of Synergia Medical

Synergia Medical, a Belgium-based company, is a leader in developing optoelectronic medical devices. Founded in 2015, it has been supported by both public and private investors, including funding from the Wallonia Region and the European Union's EIC Accelerator program. The company is primarily focused on treating drug-resistant epilepsy (DRE) using vagus nerve stimulation (VNS) technology.

EIC Accelerator Funding

In June 2022, Synergia Medical received a €2.5 million grant from the EIC Accelerator program, with potential for future equity investments. This funding recognized the company's innovative approach to neuromodulation and its potential to impact the treatment of drug-resistant epilepsy.

Advancements Since Funding

Since receiving the EIC Accelerator funding, Synergia Medical has made significant advancements in its technology. The company has developed a next-generation neuromodulation platform called NAO.VNS, which eliminates main metal components, making it immune to electromagnetic interference (EMI). This feature allows for full compatibility with MRI scans and other EMI sources, enhancing patient safety and care.

Technology Improvements

The NAO.VNS device features a fast-recharge battery with an expected lifespan of 15 years, requiring only one minute of daily charging. This technology supports energy-intensive stimulation, potentially leading to more effective therapeutic outcomes. It also enables real-time adjustments during imaging, allowing physicians to monitor brain responses and optimize therapy.

Clinical Trials and Demonstrations

Synergia Medical has successfully conducted the AURORA first-in-human clinical study for its NAO.VNS device. The study involved five patients in Belgium, with results showing strong safety and robust device performance over three months. No serious adverse events or device failures were reported. This success positions the company for pivotal FDA and CE trials.

Patents and Scientific Publications

As of the latest reports, there is no specific mention of new patents or scientific publications directly tied to the advancements since the EIC Accelerator funding. However, the company's technology developments and clinical trial results have been highlighted in various press releases and news articles.

Market Demonstration

Synergia Medical has demonstrated its technology through the AURORA clinical trial, which marks a significant step towards bringing its innovative solution to the market. The company's focus on drug-resistant epilepsy treatment positions it well in the growing neuromodulation device market.

Conclusion

Synergia Medical has made substantial strides since receiving the EIC Accelerator funding in June 2022. Its innovative NAO.VNS technology offers enhanced safety features and improved patient care, with successful clinical trials paving the way for further regulatory approvals and market entry.

Sources:

• Synergia Medical Announces Strong Results for NAO.VNS First-in-Human Study
• Synergia Medical announces strong results for NAO.VNS first-in-human study
• Synergia Medical
• Synergia Medical Announces Strong Results for NAO.VNS First-in-Human Study
• Synergia Medical
• Synergia Medical Recognised by EIC Accelerator
• Synergia implants first patients with neurostimulator for epilepsy treatment
• SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS FIRST-IN-HUMAN STUDY

5 The Partnerships and Customers

Synergia Medical: Partnerships, Customers, and Market Position

Synergia Medical, a Belgium-based company, has been at the forefront of developing innovative medical devices, particularly in the field of neural stimulation. Since receiving the EIC Accelerator funding in June 2022, the company has engaged in several partnerships and has made significant advancements in its technology and market positioning.

Partnerships and Collaborations

• IPIC Partnership: Synergia Medical has collaborated with IPIC to develop technology aimed at minimizing epileptic seizures. This partnership underscores the company's commitment to advancing treatments for epilepsy.
• Investors: Synergia Medical has attracted investments from various entities, including Newton Biocapital, SFPI, SRIW Life Sciences, Investsud, and TheClubDeal. New investors such as Invest BW and the Berrebi family have also joined, further diversifying the company's financial backing.
• EIC Accelerator: The company received a €2.5 million grant from the EIC Accelerator program, with the potential for additional equity investment in future funding rounds.

Customers and Clinical Trials

Synergia Medical's primary focus has been on developing the NAO.VNS, a non-metal optoelectronic neurostimulator for treating drug-resistant epilepsy. While specific customer names are not disclosed, the company has successfully implanted its device in several patients as part of first-in-human clinical trials conducted in Belgium and Germany.

New Relationships and Market Positioning

The partnerships and funding received since the EIC Accelerator award have significantly enhanced Synergia Medical's position in the market. The company is now recognized as a leader in optoelectronic medical devices, particularly with its pioneering work on MRI-compatible vagus nerve stimulation technology.

• Technology Advancements: The partnerships, especially with IPIC, have contributed to advancements in minimizing epileptic seizures. The use of optical fibers instead of traditional metal components allows for MRI compatibility, offering a significant advantage in monitoring treatment efficacy.
• Scaling: The financial backing from diverse investors and the EIC Accelerator grant has enabled Synergia Medical to scale its operations, preparing for larger clinical trials and regulatory submissions. This expansion is crucial for reaching a broader patient base and further establishing the company as a key player in neurostimulation solutions.

Future Prospects

With its innovative technology and strong financial support, Synergia Medical is poised to make a significant impact in the treatment of epilepsy. The company's future prospects include further clinical trials, regulatory approvals, and potentially broader applications of its neurostimulation technology.

Sources

• Synergia Medical Increases Series B Funding to €12.8 Million with an Additional €3.8 Million
• Synergia Medical Successfully Raises Series B Funding of €9 Million
• Synergia Medical Increases Series B Funding to €12.8 Million with an Additional €3.8 Million
• News and Events - Synergia Medical
• Synergia implants first patients with neurostimulator for epilepsy treatment
• IPIC, Synergia Medical develop technology to minimise epileptic seizures

6 The Hiring and Company Growth

Synergia Medical's Team Growth and Strategic Expansion Following EIC Accelerator Funding

Since receiving a €2.5 million grant from the European Innovation Council (EIC) Accelerator in October 2022, Synergia Medical has advanced its clinical programs and leadership structure to support the development of its optoelectronic neurostimulation technology. While precise current headcount figures are not publicly disclosed, the company’s growth trajectory is evident through key hires, leadership changes, and clinical milestones.

Key Developments

• Leadership Transition: Charles Nolet succeeded Attila Borbath as CEO in February 2025, bringing expertise in MedTech strategy and scaling operations. His appointment aligns with Synergia’s shift toward clinical trials and commercialization of its NAO.VNS™ device for drug-resistant epilepsy.
• Recent Leadership Additions: Dan Scherrer joined as Chief Operating Officer (COO) in November 2022 to oversee manufacturing, supply chain, and product development, reflecting a focus on operational readiness for clinical-scale production.
• Funding Growth: Synergia secured €12.8 million in Series B funding by January 2023, enabling preparations for First-In-Human trials initiated in early 2024. The EIC grant further supports R&D and future Series C fundraising efforts.

Clinical Progress Driving Hiring Needs

The successful implantation of five patients with the NAO.VNS™ system during the AURORA study (January–February 2025) suggests growing operational demands likely requiring expanded teams in:

• Clinical Operations: Managing multicenter trials across Belgium (e.g., UZ Gent).
• Manufacturing/QA: Scaling production for pivotal trials per Nolet’s stated priorities.
• Regulatory Affairs: Preparing CE mark submissions (historically targeted by late 2024/early 2025) and FDA pathways.

While explicit hiring announcements are unavailable, such expansions typically involve roles like trial managers, biomedical engineers, and regulatory specialists to support commercialization timelines noted by leadership.

---

Sources

• SYNERGIA MEDICAL ANNOUNCES: FIVE PATIENTS NOW IMPLANTED WITH NAO.VNS™ LEADERSHIP CHANGE
• Synergia Medical SA Pipeline Insight Report
• SYNERGIA MEDICAL CEO TRANSITION PRESS RELEASE (Note: Corrected URL formatting required)

⚠️ Globenewswire URL truncated; original source available via Synergia's Investor Relations page. For exact linkage limitations by platform. Additional sources referenced within text derive from prior entries (CB Insights, Fierce Biotech).

7 The Media Features and Publications

Synergia Medical: Overview and Recent Developments

Synergia Medical, a Belgian company, received EIC Accelerator funding in June 2022. Since then, the company has made significant strides in the development of next-generation neuromodulation technologies. Here is an overview of its media features, publications, podcasts, conferences, and event participation.

Media Features and Publications

Synergia Medical has been featured in several media outlets and publications for its innovative neuromodulation platform, particularly the NAO.VNS device. The company announced strong results from its first-in-human study for the NAO.VNS device, demonstrating safety and efficacy in treating drug-resistant epilepsy. There is no specific mention of Synergia Medical in major podcasts or interviews involving the company team, but they have been recognized in industry reports and conferences focused on neurotechnologies.

Content from Publications

Publications highlight Synergia Medical's work on eliminating metal components in neuromodulation devices to reduce electromagnetic interference (EMI), which is crucial for enhancing safety and reliability in medical treatments like epilepsy and depression. The company's NAO platform uses optoelectronics to provide more personalized and effective neural stimulation therapies.

Podcasts and Interviews

There is no available information on specific podcasts or interviews featuring the team of Synergia Medical. However, the company's leadership has been involved in presenting their technology at industry events.

Conferences and Event Participation

Synergia Medical participated in the LSI Emerging Medtech Summit in 2021 and 2022, where they presented their technological advancements in neurostimulation devices. The company has not been listed as a participant in major neuromodulation conferences like those organized by Neuromodec, but their involvement in the medtech community is notable through their funding and research announcements.

Involvement in Events

Since receiving the EIC Accelerator funding, Synergia Medical has focused on advancing its NAO technology. The company announced leadership changes and significant clinical milestones, including the successful implantation of the NAO.VNS device in several patients as part of the AURORA study. These developments highlight the company's active participation in advancing medical technology through clinical trials and research collaborations.

Sources

• Synergia Medical
• Synergia Medical company information
• Our technology - Synergia Medical
• Synergia Medical – MecaTech
• Highlights of Emerging Medtech Summit